Profound Medical Corp. (PROF)
$
5.33
+0.09 (1.69%)
Key metrics
Financial statements
Free cash flow per share
-0.8867
Market cap
152.1 Million
Price to sales ratio
13.3540
Debt to equity
0.0961
Current ratio
11.3148
Income quality
0.8236
Average inventory
6.3 Million
ROE
-0.7127
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Profound Medical Corp., along with its subsidiaries, is a commercial-stage medical device company engaged in the development of magnetic resonance guided ablation procedures aimed at treating prostate disease, uterine fibroids, and palliative pain in various regions including Canada, Germany, the United States, and Finland. The company’s flagship product, the TULSA-PRO system, utilizes magnetic resonance imaging technology within hospitals and treatment facilities, enhancing the precision of medical interventions. Additionally, Profound Medical Corp. provides the Sonalleve therapeutic platform, which focuses on non-invasive treatment for uterine fibroids and alleviates palliative pain associated with bone metastases. The gross profit stands at $7,037,000.00 highlighting the company’s profitability from core operations. Furthermore, the company reported an income before tax of -$26,482,355.00 showcasing its pre-tax profitability. The gross profit ratio is 0.66 reflecting the efficiency of the company's production and sales operations. In terms of earnings, the diluted EPS is -$1.12 accounting for potential share dilution. The income before tax ratio is -2.48 revealing the pre-tax margin that underscores the company's financial health. In the investment landscape, the stock is affordable at $5.33 making it suitable for budget-conscious investors. With a low average trading volume of 78,217.00 the stock indicates lower market activity, which could be a consideration for potential investors. With a market capitalization of $160,183,023.00 the company is classified as a small-cap player, allowing it to potentially capture unique growth opportunities within the market. As a key player in the Medical - Devices industry, Profound Medical Corp. significantly contributes to the overall market landscape and trends. Belonging to the Healthcare sector, the company drives innovation and growth, positioning itself as an influential entity that aims to advance medical procedures and patient care.
Is Profound Medical Corp. (PROF) a good investment?
Investing in Profound Medical Corp. (PROF) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Profound Medical Corp. (PROF)'s stock forecast?
Analysts predict Profound Medical Corp. stock to fluctuate between $3.90 (low) and $11.42 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Profound Medical Corp.'s market capitalization?
As of 2025-05-29, Profound Medical Corp.'s market cap is $160,183,023, based on 30,053,100 outstanding shares.
How does Profound Medical Corp. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Profound Medical Corp. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Profound Medical Corp. (PROF) stock?
To buy Profound Medical Corp. (PROF) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for PROF. Place an order (Market, Limit, etc.).
What is the best time to invest in Profound Medical Corp.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Profound Medical Corp. stock ever split?
Profound Medical Corp.'s last stock split was 1:10 on 2019-10-16.
How did Profound Medical Corp. perform in the last earnings report?
Revenue: $10,680,000 | EPS: -$1.12 | Growth: -17.04%.
Where can I find Profound Medical Corp.'s investor relations reports?
Visit https://www.profoundmedical.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Profound Medical Corp.?
You can explore historical data from here
What is the all-time high and low for Profound Medical Corp. stock?
All-time high: $28.97 (2021-02-08) | All-time low: $3.10 (2022-10-26).
What are the key trends affecting Profound Medical Corp. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Profound Medical Corporation (NASDAQ:PROF ) Q1 2025 - Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Stephen Kilmer - Head IR Rashed Dewan - CFO Dr. Mathieu Burtnyk - COO Tom Tamberrino - Chief Commercial Officer Arun Menawat - CEO Conference Call Participants Ben Haynor - Lake Street Capital Markets John McAuley - Stifel Michael Freeman - Raymond James Scott McAuley - Paradigm Capital Operator Good day, and thank you for standing by. Welcome to the Profound Medical First Quarter 2025 Financial Results Conference Call.
zacks.com
Profound Medical (PROF) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.26 per share a year ago.
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / May 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025 at 1:30 p.m. Eastern Time at the Metro Toronto Convention Centre.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
globenewswire.com
– First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pain, and more rapid recovery to baseline activities and overall health – TORONTO, April 29, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce initial perioperative data from the Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA procedure with radical prostatectomy (“RP”) in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. The positive perioperative results were presented yesterday by Xiaosong Meng, M.D.
globenewswire.com
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
globenewswire.com
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. (“Profound” or the “Company”) (NASDAQ: PROF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / April 20, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Profound Medical Corp. ("Profound" or the "Company") (NASDAQ:PROF). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
See all news
